Vascular endothelial growth factor +936C/T polymorphism and gastric cancer risk: A meta-analysis

Zhou,Li-Ping; Luan,Hong; Dong,Xin-Hua; Jin,Guo-Jiang; Man,Dong-Liang; Shang,Hong

doi:10.3892/etm.2011.278

Vascular endothelial growth factor +936C/T polymorphism and gastric cancer risk: A meta-analysis

Authors:
- Li-Ping Zhou
- Hong Luan
- Xin-Hua Dong
- Guo-Jiang Jin
- Dong-Liang Man
- Hong Shang
View Affiliations

Affiliations: Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang 110001, P.R. China
Published online on: May 31, 2011 https://doi.org/10.3892/etm.2011.278
Pages: 931-936

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to determine whether the vascular endothelial growth factor (VEGF) +936C/T polymorphism confers susceptibility to gastric cancer (GC) by conducting a meta-analysis. Publications addressing the association between the VEGF +936C/T polymorphism and GC risk were selected from the Pubmed, Embase and CBM databases. Data were extracted from the studies by two independent reviewers. The meta-analysis was performed using RevMan 5.0.25 and STATA 9.2 software. From these data, the odds ratio (OR) with 95% confidence interval (CI) was calculated. Finally, 8 case-control studies were retrieved reporting a total of 2,131 gastrointestinal cancer patients and 2,670 controls. Meta-analysis results showed that there was no significant association between the VEGF +936C/T polymorphism and GC risk in all comparisons of the T allele vs. C allele (OR=1.08, 95% CI 0.90‑1.30, P=0.42), CT+TT vs. CC (OR=1.08, 95% CI 0.87-1.34, P=0.49), TT vs. CC+CT (OR=1.14, 95% CI 0.85-1.53, P=0.37), TT vs. CC (OR=1.18, 95% CI 0.87-1.59, P=0.28) and TT vs. CT (OR=1.11, 95% CI 0.79-1.56, P=0.56). This meta-analysis confirms that there is a lack of association between the VEGF +936C/T polymorphism and GC risk.

View Figures

View References

1.	Brenner H, Rothenbacher D and Arndt V: Epidemiology of stomach cancer. Methods Mol Biol. 472:467–477. 2009. View Article : Google Scholar
2.	Crew KD and Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol. 12:354–362. 2006.
3.	Roder DM: The epidemiology of gastric cancer. Gastric Cancer. 5(Suppl 1): 5–11. 2002. View Article : Google Scholar
4.	Compare D, Rocco A and Nardone G: Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci. 14:302–308. 2010.
5.	Krejs GJ: Gastric cancer: epidemiology and risk factors. Dig Dis. 28:600–603. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
7.	Uemura N, Okamoto S, Yamamoto S, et al: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 345:784–789. 2001. View Article : Google Scholar
8.	Liu C and Russell RM: Nutrition and gastric cancer risk: an update. Nutr Rev. 66:237–249. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Oliveira C, Seruca R and Carneiro F: Hereditary gastric cancer. Best Prac Res Clin Gastroenterol. 23:147–157. 2009. View Article : Google Scholar
10.	González CA, Sala N and Capellá G: Genetic susceptibility and gastric cancer risk. Int J Cancer. 100:249–260. 2002.
11.	Perera FP and Weinstein IB: Molecular epidemiology: recent advances and future directions. Carcinogenesis. 21:517–524. 2000. View Article : Google Scholar : PubMed/NCBI
12.	Ames BN: Cancer prevention and diet: help from single nucleotide polymorphisms. Proc Natl Acad Sci USA. 96:12216–12218. 1999. View Article : Google Scholar : PubMed/NCBI
13.	McMahon G: VEGF receptor signaling in tumor angiogenesis. Oncologist. 5(Suppl 1): 3–10. 2000. View Article : Google Scholar
14.	Gaur P, Bose D, Samuel S and Ellis LM: Targeting tumor angiogenesis. Semin Oncol. 36(Suppl 1): 12–19. 2009. View Article : Google Scholar
15.	Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2:795–803. 2002. View Article : Google Scholar : PubMed/NCBI
16.	Vincenti V, Cassano C, Rocchi M and Persico G: Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 93:1493–1495. 1996. View Article : Google Scholar
17.	Otrock ZK, Makarem JA and Shamseddine AI: Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis. 38:258–268. 2007. View Article : Google Scholar : PubMed/NCBI
18.	Zhang Z, Neiva KG, Lingen MW, et al: VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ. 17:499–512. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Ichikura T, Tomimatsu S, Ohkura E, et al: Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. J Surg Oncol. 78:132–137. 2001. View Article : Google Scholar : PubMed/NCBI
20.	Lieto E, Ferraraccio F, Orditura M, et al: Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 15:69–79. 2008. View Article : Google Scholar
21.	Smith MG, Hold GL, Tahara E, et al: Cellular and molecular aspects of gastric cancer. World J Gastroenterol. 12:2979–2990. 2006.
22.	Watson CJ, Webb NJ, Bottomley MJ, et al: Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 12:1232–1235. 2006. View Article : Google Scholar : PubMed/NCBI
23.	Vandenbroucke JP, von Elm E, Altman DG, et al: Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology. 18:805–835. 2007. View Article : Google Scholar
24.	Zintzaras E and Ioannidis JP: Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 28:123–137. 2005. View Article : Google Scholar : PubMed/NCBI
25.	Higgins JP and Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 21:1539–1158. 2002. View Article : Google Scholar : PubMed/NCBI
26.	Viechtbauer W: Confidence intervals for the amount of heterogeneity in meta-analysis. Stat Med. 26:37–52. 2007. View Article : Google Scholar : PubMed/NCBI
27.	Peters JL, Sutton AJ, Jones DR, et al: Comparison of two methods to detect publication bias in meta-analysis. JAMA. 295:676–680. 2006. View Article : Google Scholar : PubMed/NCBI
28.	Tzanakis N, Gazouli M, Rallis G, et al: Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol. 94:624–630. 2006. View Article : Google Scholar : PubMed/NCBI
29.	Chae YS, Kim JG, Sohn SK, et al: Investigation of vascular endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer. Oncology. 71:266–272. 2006. View Article : Google Scholar : PubMed/NCBI
30.	Bae SJ, Ahn DH, Hong SP, et al: Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936C>T) gene and patients with stomach cancer. Yonsei Med J. 49:783–791. 2008.
31.	Ke Q, Liang J, Wang LN, et al: Potentially functional polymorphisms of the vascular endothelial growth factor gene and risk of gastric cancer. Mol Carcinog. 47:647–651. 2008. View Article : Google Scholar : PubMed/NCBI
32.	Al-Moundhri MS, Al-Nabhani M, Burney IA, et al: Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms: a case-control study in an Omani population. Mol Carcinog. 48:1170–1176. 2009. View Article : Google Scholar : PubMed/NCBI
33.	Guan X, Zhao H, Niu J, et al: The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. BMC Gastroenterol. 9:772009.
34.	Tahara T, Shibata T, Nakamura M, et al: Effect of polymorphisms in the 3′ untranslated region (3′-UTR) of vascular endothelial growth factor gene on gastric cancer and peptic ulcer diseases in Japan. Mol Carcinog. 48:1030–1037. 2009.
35.	Xia HZ, Wu Q, Liu Y, et al: Association ofVEGF rs3025039 and rs3025021 with VEGF and COX-2 expression in gastric cancer tissues. J Clin Exp Pathol. 26:139–143. 2010.
36.	Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
37.	Uthoff SM, Duchrow M, Schmidt MH, et al: VEGF isoforms and mutations in human colorectal cancer. Int J Cancer. 101:32–36. 2002. View Article : Google Scholar : PubMed/NCBI
38.	Yuan A, Yu CJ, Chen WJ, et al: Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer. 89:475–483. 2000. View Article : Google Scholar : PubMed/NCBI
39.	Krippl P, Langsenlehner U, Renner W, et al: A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer. 106:468–471. 2003. View Article : Google Scholar : PubMed/NCBI
40.	Lin CC, Wu HC, Tsai FJ, et al: Vascular endothelial growth factor gene -460 C/T polymorphism is a biomarker for prostate cancer. Urology. 62:374–377. 2003. View Article : Google Scholar : PubMed/NCBI
41.	Taylor JG, Choi EH, Foster CB, et al: Using genetic variation to study human disease. Trends Mol Med. 7:507–512. 2001. View Article : Google Scholar : PubMed/NCBI